Leaps by Bayer, Matrix-backed AyurMaya and Amgen Ventures led a $200m Series B funding round in ReCode Therapeutics, a developer integrated genetic medicines company, with participation from Pfizer Ventures, EcoR1 Capital, Sanofi Ventures, Orbimed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, Osage University Partners, Tekla Capital Management, Superstring Capital and NS Investment. “The ability to directly target specific organs and cells beyond the liver remains a key challenge for genetic medicines. At Leaps by Bayer, we strongly focus on finding breakthrough solutions that have the potential to make a meaningful difference for people with rare genetic diseases, and we believe ReCode is a unique company in our industry whose innovations have the potential to fundamentally shift an entire area of genetic medicine," Juergen Eckhardt, Leaps by Bayer CEO.